$59.76 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
Equities research analysts forecast that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report $59.76 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Halozyme Therapeutics’ earnings, with the lowest sales estimate coming in at $58.67 million and the highest estimate coming in at $61.89 million. Halozyme Therapeutics reported sales of $189.56 million in the same quarter last year, which would suggest a negative year over year growth rate of 68.5%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 19th.
According to Zacks, analysts expect that Halozyme Therapeutics will report full year sales of $153.54 million for the current financial year, with estimates ranging from $150.30 million to $160.00 million. For the next year, analysts forecast that the company will post sales of $151.23 million, with estimates ranging from $129.27 million to $164.68 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.04. The business had revenue of $25.60 million during the quarter, compared to the consensus estimate of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The business’s revenue was down 59.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.02 EPS.
Shares of NASDAQ HALO traded down $0.55 during midday trading on Wednesday, reaching $15.58. 665,197 shares of the stock were exchanged, compared to its average volume of 918,731. The company has a market capitalization of $2.33 billion, a P/E ratio of 34.62 and a beta of 1.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.09 and a quick ratio of 2.96. Halozyme Therapeutics has a twelve month low of $14.33 and a twelve month high of $21.48.
In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 161,246 shares of the business’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $17.15, for a total value of $2,765,368.90. Following the completion of the transaction, the insider now owns 3,562,388 shares in the company, valued at $61,094,954.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Randal J. Kirk sold 644,998 shares of the business’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $18.08, for a total transaction of $11,661,563.84. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at approximately $64,407,975.04. The disclosure for this sale can be found here. Insiders sold a total of 2,000,706 shares of company stock valued at $35,509,187 in the last quarter. 14.10% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the business. Granite Investment Partners LLC grew its stake in shares of Halozyme Therapeutics by 0.4% in the second quarter. Granite Investment Partners LLC now owns 734,528 shares of the biopharmaceutical company’s stock worth $12,391,000 after acquiring an additional 2,892 shares in the last quarter. Amalgamated Bank grew its stake in shares of Halozyme Therapeutics by 19.3% in the second quarter. Amalgamated Bank now owns 19,053 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 3,077 shares in the last quarter. Xact Kapitalforvaltning AB grew its stake in shares of Halozyme Therapeutics by 18.5% in the second quarter. Xact Kapitalforvaltning AB now owns 21,769 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 3,400 shares in the last quarter. Swiss National Bank grew its stake in shares of Halozyme Therapeutics by 1.6% in the third quarter. Swiss National Bank now owns 226,000 shares of the biopharmaceutical company’s stock worth $4,106,000 after acquiring an additional 3,500 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in shares of Halozyme Therapeutics by 15.9% in the second quarter. CIBC Private Wealth Group LLC now owns 25,766 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 3,541 shares in the last quarter. Institutional investors and hedge funds own 85.52% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.